Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Ibrutinib, a first-in-class once-daily oral Bruton tyrosine kinase inhibitor indicated for chronic lymphocytic leukemia (CLL), is continued until progressive disease or unacceptable toxicity. We conducted an integrated safety analysis of single-agent ibrutinib from randomized phase 3 studies PCYC-11...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Coutre, Steven E., Byrd, John C., Hillmen, Peter, Barrientos, Jacqueline C., Barr, Paul M., Devereux, Stephen, Robak, Tadeusz, Kipps, Thomas J., Schuh, Anna, Moreno, Carol, Furman, Richard R., Burger, Jan A., O’Dwyer, Michael, Ghia, Paolo, Valentino, Rudolph, Chang, Stephen, Dean, James P., James, Danelle F., O’Brien, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595265/
https://ncbi.nlm.nih.gov/pubmed/31196847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018028761
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados